tetano
Editor, Senior Moderator
Antimicrob Steward Healthc Epidemiol
. 2023 Aug 4;3(1):e133.
doi: 10.1017/ash.2022.375. eCollection 2023. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020-April 2021
Rachel E Bosserman[SUP] 1 [/SUP], Christopher W Farnsworth[SUP] 2 [/SUP], Caroline A O'Neil[SUP] 1 [/SUP], Candice Cass[SUP] 1 [/SUP], Daniel Park[SUP] 1 [/SUP], Claire Ballman[SUP] 2 [/SUP], Meghan A Wallace[SUP] 2 [/SUP], Emily Struttmann[SUP] 1 [/SUP], Henry Stewart[SUP] 1 [/SUP], Olivia Arter[SUP] 1 [/SUP], Kate Peacock[SUP] 1 [/SUP], Victoria J Fraser[SUP] 1 [/SUP], Philip J Budge[SUP] 1 [/SUP], Margaret A Olsen[SUP] 1 [/SUP], Carey-Ann D Burnham[SUP] 2 [/SUP], Hilary M Babcock[SUP] 1 [/SUP], Jennie H Kwon[SUP] 1 [/SUP]; CDC Prevention Epicenters
Affiliations
Objective: To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity.
Design: Prospective cohort study.
Setting: An academic, tertiary-care hospital in St. Louis, Missouri.
Participants: The study included 400 HCP aged ≥18 years who potentially worked with coronavirus disease 2019 (COVID-19) patients and had no known history of COVID-19; 309 of these HCP also completed a follow-up visit 70-160 days after enrollment. Enrollment visits took place between September and December 2020. Follow-up visits took place between December 2020 and April 2021.
Methods: At each study visit, participants underwent SARS-CoV-2 IgG N-antibody testing using the Abbott SARS-CoV-2 IgG assay and completed a survey providing information about demographics, job characteristics, comorbidities, symptoms, and potential SARS-CoV-2 exposures.
Results: Participants were predominately women (64%) and white (79%), with median age of 34.5 years (interquartile range [IQR], 30-45). Among the 400 HCP, 18 (4.5%) were seropositive for IgG N-antibodies at enrollment. Also, 34 (11.0%) of 309 were seropositive at follow-up. HCP who reported having a household contact with COVID-19 had greater likelihood of seropositivity at both enrollment and at follow-up.
Conclusions: In this cohort of HCP during the first wave of the COVID-19 pandemic, ∼1 in 20 had serological evidence of prior, undocumented SARS-CoV-2 infection at enrollment. Having a household contact with COVID-19 was associated with seropositivity.
. 2023 Aug 4;3(1):e133.
doi: 10.1017/ash.2022.375. eCollection 2023. Seroprevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) antibodies among healthcare personnel in the Midwestern United States, September 2020-April 2021
Rachel E Bosserman[SUP] 1 [/SUP], Christopher W Farnsworth[SUP] 2 [/SUP], Caroline A O'Neil[SUP] 1 [/SUP], Candice Cass[SUP] 1 [/SUP], Daniel Park[SUP] 1 [/SUP], Claire Ballman[SUP] 2 [/SUP], Meghan A Wallace[SUP] 2 [/SUP], Emily Struttmann[SUP] 1 [/SUP], Henry Stewart[SUP] 1 [/SUP], Olivia Arter[SUP] 1 [/SUP], Kate Peacock[SUP] 1 [/SUP], Victoria J Fraser[SUP] 1 [/SUP], Philip J Budge[SUP] 1 [/SUP], Margaret A Olsen[SUP] 1 [/SUP], Carey-Ann D Burnham[SUP] 2 [/SUP], Hilary M Babcock[SUP] 1 [/SUP], Jennie H Kwon[SUP] 1 [/SUP]; CDC Prevention Epicenters
Affiliations
- PMID: 37592963
- PMCID: PMC10428156
- DOI: 10.1017/ash.2022.375
Objective: To determine the prevalence of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG nucleocapsid (N) antibodies among healthcare personnel (HCP) with no prior history of COVID-19 and to identify factors associated with seropositivity.
Design: Prospective cohort study.
Setting: An academic, tertiary-care hospital in St. Louis, Missouri.
Participants: The study included 400 HCP aged ≥18 years who potentially worked with coronavirus disease 2019 (COVID-19) patients and had no known history of COVID-19; 309 of these HCP also completed a follow-up visit 70-160 days after enrollment. Enrollment visits took place between September and December 2020. Follow-up visits took place between December 2020 and April 2021.
Methods: At each study visit, participants underwent SARS-CoV-2 IgG N-antibody testing using the Abbott SARS-CoV-2 IgG assay and completed a survey providing information about demographics, job characteristics, comorbidities, symptoms, and potential SARS-CoV-2 exposures.
Results: Participants were predominately women (64%) and white (79%), with median age of 34.5 years (interquartile range [IQR], 30-45). Among the 400 HCP, 18 (4.5%) were seropositive for IgG N-antibodies at enrollment. Also, 34 (11.0%) of 309 were seropositive at follow-up. HCP who reported having a household contact with COVID-19 had greater likelihood of seropositivity at both enrollment and at follow-up.
Conclusions: In this cohort of HCP during the first wave of the COVID-19 pandemic, ∼1 in 20 had serological evidence of prior, undocumented SARS-CoV-2 infection at enrollment. Having a household contact with COVID-19 was associated with seropositivity.